Anesthetic Effect - Pipeline Review, H1 2018

  • ID: 4479912
  • Drug Pipelines
  • 82 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Biolab Farmaceutica Ltda
  • Crescita Therapeutics Inc
  • Expanesthetics Inc
  • Lannett Company Inc
  • Paion AG
  • MORE
Anesthetic Effect - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 2, 2, 14 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Biolab Farmaceutica Ltda
  • Crescita Therapeutics Inc
  • Expanesthetics Inc
  • Lannett Company Inc
  • Paion AG
  • MORE
Introduction

Report Coverage

Anesthetic Effect - Overview

Anesthetic Effect - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anesthetic Effect - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anesthetic Effect - Companies Involved in Therapeutics Development

4P Therapeutics LLC

Biolab Farmaceutica Ltda

Crescita Therapeutics Inc

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Jiangsu Hengrui Medicine Co Ltd

Lannett Company Inc

Lee's Pharmaceutical Holdings Ltd

Paion AG

Phosphagenics Ltd

Physica Pharma

Primex Pharmaceuticals Oy

Recro Pharma Inc

The Medicines Company

Anesthetic Effect - Drug Profiles

alphaxalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carboetomidate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-09 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Flexicaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSK-3486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine + prilocaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methoxycarbonyl Carboetomidate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methoxycarbonyl Etomidate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midazolam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHY-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Anesthetic Effect - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anesthetic Effect - Dormant Projects

Anesthetic Effect - Discontinued Products

Anesthetic Effect - Product Development Milestones

Featured News & Press Releases

Dec 01, 2017: Lannett Announces FDA Acceptance Of 505(b)(2) New Drug Application For Cocaine Hydrochloride Topical Solution, A Proprietary Anesthetic Product

Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera

Nov 09, 2017: Phosphagenics Provides Update on TPM/Propofol Development Program

Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU

Sep 25, 2017: Lannett's Board Of Directors Initiates CEO Search

Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial

Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia

Oct 27, 2016: Lannett Announces Successful Phase III Clinical Trial Results For Proprietary C-Topical Product

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anesthetic Effect, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H1 2018

Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H1 2018

Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2018

Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2018

Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2018

Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Anesthetic Effect - Pipeline by Lannett Company Inc, H1 2018

Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Anesthetic Effect - Pipeline by Paion AG, H1 2018

Anesthetic Effect - Pipeline by Phosphagenics Ltd, H1 2018

Anesthetic Effect - Pipeline by Physica Pharma, H1 2018

Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H1 2018

Anesthetic Effect - Pipeline by Recro Pharma Inc, H1 2018

Anesthetic Effect - Pipeline by The Medicines Company, H1 2018

Anesthetic Effect - Dormant Projects, H1 2018

Anesthetic Effect - Dormant Projects, H1 2018 (Contd..1), H1 2018

Anesthetic Effect - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Anesthetic Effect, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4P Therapeutics LLC
  • Biolab Farmaceutica Ltda
  • Crescita Therapeutics Inc
  • Drawbridge Pharmaceuticals Pty Ltd
  • Expanesthetics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lannett Company Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Paion AG
  • Phosphagenics Ltd
  • Physica Pharma
  • Primex Pharmaceuticals Oy
  • Recro Pharma Inc
  • The Medicines Company
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll